Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2017

Open Access 01-12-2017 | Research article

Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

Authors: Xiaoyan Lu, Caitlin Smare, Chrispin Kambili, Antoine C. El Khoury, Lara J. Wolfson

Published in: BMC Health Services Research | Issue 1/2017

Login to get access

Abstract

Background

Less than one-third of patients who are estimated to be infected with multidrug-resistant tuberculosis (MDR-TB) receive MDR-TB treatment regimens, and only 48% of those who received treatment have successful outcomes. Despite current regimens, newer, more effective and cost-effective approaches to treatment are needed. The aim of the study was to project health outcomes and impact on healthcare resources of adding bedaquiline to the treatment regimen of MDR-TB in selected high burden countries: Estonia, Russia, South Africa, Peru, China, the Philippines, and India.

Methods

This study adapted an existing Markov model to estimate the health outcomes and impact on total healthcare costs of adding bedaquiline to current MDR-TB treatment regimens. A price threshold analysis was conducted to determine the price range at which bedaquiline would be cost-effective.

Results

Adding bedaquiline to the background regimen (BR) resulted in increased disability-adjusted life years (DALYs) averted, and reduced total healthcare costs (excluding treatment acquisition costs) compared with BR alone in all countries analyzed. Addition of bedaquiline to BR resulted in savings to healthcare costs compared with BR alone in all countries analyzed, with the highest impact expected in Russia (US$194 million) and South Africa (US$43 million). The price per regimen at which bedaquiline would be cost-effective ranged between US$23,904-US$203,492 in Estonia, Russia, Peru, South Africa, and China (high and upper middle-income countries) and between US$6,996-US$20,323 in the Philippines and India (lower middle-income countries); however, these cost-effective prices do not necessarily address concerns about affordability.

Conclusions

Adding bedaquiline to BR provides improvements in health outcomes and reductions in healthcare costs in high MDR-TB burden countries. The range of prices per regimen for which bedaquiline would be cost-effective varied between countries.
Appendix
Available only for authorised users
Literature
1.
CDC. Notice to readers: revised definition of extensively drug-resistant tuberculosis. Morb Mortal Wkly Rep. 2006;55(43):1176.
2.
3.
WHO. Guidelines for the programmatic management of drug-resistant tuberculosis - Emergency update. 2008.
4.
Janssen. Sirturo: Prescribing information. 2012.
5.
Janssen. Sirturo: Summary of product characteristics. 2015.
6.
WHO. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis - Interim policy guidance. 2013.
7.
WHO, Vassall A. Cost-effectiveness of introducing Bedaquiline in MDR-TB regimens - An exploratory analysis. 2013 Jan 26.
8.
Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics. 2012;30(1):63–80.CrossRefPubMed
9.
Wolfson LJ, Walker A, Hettle R, Lu X, Kambili C, Murungi A, et al. Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK. PLoS ONE. 2015;10(3):e0120763.CrossRefPubMedPubMedCentral
10.
Murray CJ. Qualifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72:429–45.PubMedPubMedCentral
11.
12.
Diacon AH, Pym A, Grobusch MP, Rios JM de l, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723–32.CrossRefPubMed
13.
FDA. Treatment of patients with MDR-TB-TMC207 (bedaquiline) - Anti-Infective Drugs Advisory Committee Meeting. 2012 Nov 28.
14.
15.
Health Protection Agency. Tuberculosis in the UK. 2013.
16.
Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2129–43.CrossRefPubMed
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS ONE. 2013;8(1):e54587.CrossRefPubMedPubMedCentral
27.
Zhang X, Nievera M, Carlos J, Lucero M, Bibera G, Atienza M, et al. Cost-effectiveness analysis of pneumococcal vaccination with pneumococcal polysaccharide NTHi protein D conjugate vaccine in the Philippines. Value Health Reg Issues. 2014;3:156–66.CrossRef
28.
Gupta SK. Proposed pharmacoeconomics guidelines for India (PEG_I). 2013.
29.
30.
31.
32.
Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint tuberculosis committee of the British thoracic society. Thorax. 1998;53(7):536–48.CrossRef
33.
WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. 2014.
34.
Liu CH, Li L, Chen Z, Wang Q, Hu YL, Zhu B, et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS ONE. 2011;6(4):e19399.CrossRefPubMedPubMedCentral
35.
Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS ONE. 2011;6(4):e17601.CrossRefPubMedPubMedCentral
36.
UK Department of Health. National Health System: Reference costs 2011-2012. 2012
37.
38.
Lu C, Liu Q, Sarma A, Fitzpatrick C, Falzon D, Mitnick CD. A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment. PLoS ONE. 2013;8(2):e56074.CrossRefPubMedPubMedCentral
39.
Muniyandi M, Rajeswari R, Balasubramanian R. Estimating provider cost for treating patients with tuberculosis under Revised National Tuberculosis Control Programme (RNTCP). Indian J Tuberc. 2006;53:12–7.
40.
Jit M, Stagg HR, Aldridge RW, White PJ, Abubakar I. Dedicated outreach service for hard to reach patients with tuberculosis in London: observational study and economic evaluation. BMJ. 2011;343:d5376.CrossRefPubMedPubMedCentral
41.
Kind P, Hardman G, Macran S. UK population norms for EQ-5D. 1999
42.
Guglielmetti L, Le DD, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Metivier N, Robert J. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis. 2015;60(2):188–94.CrossRefPubMed
43.
Ndjeka N, Conradie F, Hughes J, Schnipel K, Cox H, Bantubani N, Ferreira H, Maartens G, Master I, Meintjes G, Padanilam X, Pym A, Siwendu S, Variava E. Safe and effective bedaquiline treatment of drug-resistant tuberculosis (DR-TB) within the National Bedaquiline Clinical Access Programme in South Africa. Barcelona, Spain: 45th Union World Conference on Lung Health; 2014.
Metadata
Title
Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries
Authors
Xiaoyan Lu
Caitlin Smare
Chrispin Kambili
Antoine C. El Khoury
Lara J. Wolfson
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2017
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-016-1931-3

Other articles of this Issue 1/2017

BMC Health Services Research 1/2017 Go to the issue

Research article

Implementing the Emergency Triage, Assessment and Treatment plus admission care (ETAT+) clinical practice guidelines to improve quality of hospital care in Rwandan district hospitals: healthcare workers’ perspectives on relevance and challenges

Debate

Sustainability in Health care by Allocating Resources Effectively (SHARE) 10: operationalising disinvestment in a conceptual framework for resource allocation

Erratum

Erratum to: costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation – a nationwide cohort study

Research article

The role of consumer perspectives in estimating population need for substance use services: a scoping review

Research article

Perceptions of quality across the maternal care continuum in the context of a health financing intervention: Evidence from a mixed methods study in rural Malawi

Research article

Validation of an instrument to assess the delivery of patient-centred care to people with intellectual disabilities as perceived by professionals